These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 35460070)
1. Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial. Gottschlich A; Gondara L; Smith LW; Cook D; Martin RE; Lee M; Peacock S; Proctor L; Stuart G; Krajden M; Franco EL; van Niekerk D; Ogilvie G Int J Cancer; 2022 Sep; 151(6):897-905. PubMed ID: 35460070 [TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804 [TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus test with cytology triage in organized screening for cervical cancer. Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407 [TBL] [Abstract][Full Text] [Related]
4. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study. Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286 [TBL] [Abstract][Full Text] [Related]
5. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J; Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449 [TBL] [Abstract][Full Text] [Related]
7. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596 [TBL] [Abstract][Full Text] [Related]
8. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658 [TBL] [Abstract][Full Text] [Related]
9. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors]. Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243 [TBL] [Abstract][Full Text] [Related]
10. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N; J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502 [TBL] [Abstract][Full Text] [Related]
11. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084 [TBL] [Abstract][Full Text] [Related]
12. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579 [TBL] [Abstract][Full Text] [Related]
13. Cervical Cancer Screening: A Review. Perkins RB; Wentzensen N; Guido RS; Schiffman M JAMA; 2023 Aug; 330(6):547-558. PubMed ID: 37552298 [TBL] [Abstract][Full Text] [Related]
14. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT. Gilham C; Sargent A; Kitchener HC; Peto J Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027 [TBL] [Abstract][Full Text] [Related]
15. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy. Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948 [TBL] [Abstract][Full Text] [Related]
16. Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study. Gottschlich A; Hong Q; Gondara L; Alam MS; Cook DA; Martin RE; Lee M; Melnikow J; Peacock S; Proctor L; Stuart G; Franco EL; Krajden M; Smith LW; Ogilvie GS Cancer Epidemiol Biomarkers Prev; 2024 Jul; 33(7):904-911. PubMed ID: 38773687 [TBL] [Abstract][Full Text] [Related]
17. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397 [TBL] [Abstract][Full Text] [Related]
18. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study. Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283 [TBL] [Abstract][Full Text] [Related]
19. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population]. Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341 [No Abstract] [Full Text] [Related]
20. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs. Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]